The New Structures of Platform Deals
This article was originally published in Start Up
Executive Summary
Platform deals are still occurring, but thanks to the changing economics of the pharmaceutical industry, particularly drug companies' infatuation with late-stage deals, platform deal structures are changing. Dollar values are generally lower; tech transfer is more common; royalties and product-based milestones rarer.
You may also be interested in...
Why Clinical Trials Fail Unexpectedly
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.
Why Investors Adopt Orphans
Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?
Can Anyone Make Money from Biomarkers?
Biomarkers are being used now across the whole pharmaceutical value chain, but it's unlikely we'll see a surge in the number of VC-backed biomarker discovery start-ups until the business models are proven.